Cargando…

Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study

Veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) is a potentially life-threatening complication of haematopoietic cell transplantation (HCT) conditioning. The DEFIFrance post-marketing registry study evaluated effectiveness and safety in patients who received defibrotide. It collecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mohty, Mohamad, Blaise, Didier, Peffault de Latour, Régis, Labopin, Myriam, Bourhis, Jean Henri, Bruno, Benedicte, Ceballos, Patrice, Detrait, Marie, Gandemer, Virginie, Huynh, Anne, Izadifar-Legrand, Faezeh, Jubert, Charlotte, Labussière-Wallet, Hélène, Lebon, Delphine, Maury, Sébastien, Paillard, Catherine, Pochon, Cécile, Renard, Cecile, Rialland, Fanny, Schneider, Pascale, Sirvent, Anne, Asubonteng, Kobby, Guindeuil, Gwennaëlle, Yakoub-Agha, Ibrahim, Dalle, Jean-Hugues
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10073014/ https://www.ncbi.nlm.nih.gov/pubmed/36564486 http://dx.doi.org/10.1038/s41409-022-01900-6

Ejemplares similares

P1355: VENO-OCCLUSIVE DISEASE/SINUSOIDAL OBSTRUCTION SYNDROME (VOD/SOS) AFTER AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION (HCT): OUTCOMES OF DEFIBROTIDE-TREATED ADULT PATIENTS FROM THE DEFIFRANCE STUDY
por: Mohty, M., et al.
Publicado: (2022)

Clofarabine/busulfan-based reduced intensity conditioning regimens provides very good survivals in acute myeloid leukemia patients in complete remission at transplant: a retrospective study on behalf of the SFGM-TC
por: Le Bourgeois, Amandine, et al.
Publicado: (2018)

Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
por: Halaburda, Kazimierz, et al.
Publicado: (2020)

Allogeneic peripheral blood stem cell transplantation with anti-thymocyte globulin versus allogeneic bone marrow transplantation without anti-thymocyte globulin
por: Baron, Frédéric, et al.
Publicado: (2020)

Defibrotide for hepatic veno-occlusive disease
Publicado: (2021)

Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT
por: Pavlů, Jiří, et al.
Publicado: (2019)

Clofarabine versus fludarabine‐based reduced‐intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
por: Chevallier, Patrice, et al.
Publicado: (2016)

Total body irradiation versus busulfan based intermediate intensity conditioning for stem cell transplantation in ALL patients >45 years—a registry-based study by the Acute Leukemia Working Party of the EBMT
por: Hirschbühl, Klaus, et al.
Publicado: (2023)

Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC)
por: Pochon, Cécile, et al.
Publicado: (2021)

Pharmacokinetic profile of defibrotide in patients with renal impairment
por: Tocchetti, Paola, et al.
Publicado: (2016)

Defibrotide in the treatment of hepatic veno-occlusive disease
por: Fulgenzi, Alessandro, et al.
Publicado: (2016)

Pharmacokinetics and Safety of Defibrotide in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia
por: Schmaelter, Ann-Kristin, et al.
Publicado: (2020)

Defibrotide Therapy for SARS-CoV-2 ARDS
por: Frame, David, et al.
Publicado: (2022)

Defibrotide Has a Role in COVID-19 Therapy
por: Macciò, Antonio, et al.
Publicado: (2022)

Endothelium-protective, histone-neutralizing properties of the polyanionic agent defibrotide
por: Shi, Hui, et al.
Publicado: (2021)

Interest of the preventive and curative use of defibrotide on the occurrence and severity of sinusoidal obstruction syndrome after hematopoietic stem cell transplant in children
por: Rudebeck, Carl J., et al.
Publicado: (2022)

Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2019)

Measurable residual disease, FLT3‐ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1‐mutated acute myeloid leukemia
por: Al Hamed, Rama, et al.
Publicado: (2022)

Thick primary melanoma has a heterogeneous tumor biology: an institutional series
por: Meguerditchian, Ari-Nareg, et al.
Publicado: (2011)

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial
por: Cortes, Jorge E., et al.
Publicado: (2022)

Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
por: Palomo, Marta, et al.
Publicado: (2019)

Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
por: Yanik, Gregory A, et al.
Publicado: (2021)

Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide
por: Kong, Seom Gim, et al.
Publicado: (2022)

Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome
por: Liu, Zhenli, et al.
Publicado: (2022)

Acute Graft-vs.-Host Disease-Associated Endothelial Activation in vitro Is Prevented by Defibrotide
por: Martinez-Sanchez, Julia, et al.
Publicado: (2019)

Pre-Exposure to Defibrotide Prevents Endothelial Cell Activation by Lipopolysaccharide: An Ingenuity Pathway Analysis
por: Orlando, Nicoletta, et al.
Publicado: (2020)

The importance of endothelial protection: the emerging role of defibrotide in reversing endothelial injury and its sequelae
por: Richardson, Paul G., et al.
Publicado: (2021)

Respiratory Virus Infections in Hematopoietic Cell Transplant Recipients
por: Pochon, Cécile, et al.
Publicado: (2019)

Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2021)

A phase II, prospective, randomized, open-label study of defibrotide added to standard-of-care prophylaxis for the prevention of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation
por: Hudspeth, Michelle, et al.
Publicado: (2022)

Defibrotide (Defitelio): A New Addition to the Stockpile of Food and Drug Administration-approved Oligonucleotide Drugs
por: Stein, Cy, et al.
Publicado: (2016)

Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients
por: Squillaci, Domenica, et al.
Publicado: (2023)

HSCT may lower leukemia risk in ELANE neutropenia: a before–after study from the French Severe Congenital Neutropenia Registry
por: Rotulo, Gioacchino Andrea, et al.
Publicado: (2020)

Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT)
por: Saraceni, Francesco, et al.
Publicado: (2020)

Comment faire face à un événement inattendu pouvant modifier l’activité normale de thérapie cellulaire ? Recommandations de la Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
por: Bay, Jacques Olivier, et al.
Publicado: (2021)

Defibrotide enhances fibrinolysis in human endotoxemia – a randomized, double blind, crossover trial in healthy volunteers
por: Schoergenhofer, Christian, et al.
Publicado: (2019)

Defibrotide inhibits donor leucocyte‐endothelial interactions and protects against acute graft‐versus‐host disease
por: García‐Bernal, David, et al.
Publicado: (2020)

Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS)
por: Richardson, Paul, et al.
Publicado: (2019)

Use of Defibrotide in Patients with COVID-19 Pneumonia; Results of the Defi-VID19 Phase 2 Trial
por: Ruggeri, Annalisa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kadndn4j6nk8c32qr7rrg24hrl